- February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
- December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
- November 2015
Caroline Robert on new developments in immunotherapy.
- October 2015
Milena Sant on the latest results from the EUROCARE study.
- September 2015
The science behind the IARC code that could reduce cancer in Europe.
- July/August 2015
Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
- June 2015
Lesley Seymour and Jan Bogaerts on the future of RECIST.
- May 2015
Paul Workman on strategies for overcoming resistance to new drugs.
- April 2015
Highlights from the TAT Congress in Paris.
- March 2015
Christopher Wild on the exposome, a measure of environmental exposure.
EJC News Focus – March 2013
'New impetus is needed' to tackle the global burden of childhood cancer
Improvements in child cancer survival rates mean that 80% are now potentially curable with current treatments. Despite this, almost 100,000 children under 15 die from cancer, every year.
In a new Lancet Oncology Series, experts are challenging public policy on childhood cancer and calling for new determination to focus on the specific needs of children and young people with cancer.
In Europe and the States, for example, increasingly strict regulations governing clinical trials and data protection are hampering research and slowing down the development of new treatments for childhood cancers. In poorer countries, the key problem may be poor availability of basic healthcare but much has been achieved in some by politicians motivated to create sustainable infrastructure.
Richard Sullivan (King's Health Partners Integrated Cancer Centre, London) co-edited the series, and is also editor of the new online Journal of Cancer Policy, which will publish follow-up papers on paediatric oncology from this autumn. In this month's EJC News Focus, he tells Helen Saul that the current political climate is 'lukewarm' on the issue of childhood cancer, and why that needs to change.